Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran (SKU B6848) is a highly selective agonist for HM74A/GPR109A and GPR109B hydroxycarboxylic acid receptors, facilitating precise modulation of lipid metabolism in research contexts (Ye et al., 2025). Its structure and binding modes have been resolved at atomic resolution using cryo-EM, confirming target specificity and ligand interaction mechanisms. Supplied by APExBIO at ≥98% purity, Acifran exhibits low solubility (<21.82 mg/ml in ethanol, DMSO) and is intended exclusively for scientific research, not clinical use (APExBIO product page). Rapid workflow integration and reproducible effects make it a reference tool in G-protein coupled receptor assays. Misconceptions regarding its use in diagnostics or as a general hypolipidemic agent are clarified herein.

Biological Rationale

Lipid metabolism is regulated by a network of G-protein coupled receptors (GPCRs), including the hydroxycarboxylic acid receptors HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) (Ye et al., 2025). These receptors detect metabolic intermediates and modulate downstream signaling to control lipid breakdown and synthesis. Disruption of these pathways is implicated in metabolic disorders, including dyslipidemia and type 2 diabetes. Selective agonists like Acifran enable controlled activation of these receptors, allowing researchers to dissect pathway-specific effects and receptor selectivity (entinostat.net).

Mechanism of Action of Acifran

Acifran acts as a selective agonist for HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) receptors. Upon binding, Acifran engages the orthosteric pocket of these GPCRs, as confirmed by high-resolution cryo-EM structures (3.18 Å for HCAR3, 2.72 Å for HCAR2) (Ye et al., 2025). Key π–π interactions and specific residue contacts (e.g., F107^3.32 in HCAR3) underlie its selectivity. This interaction reduces intracellular cAMP levels in HEK-293 cells, modulating lipid metabolism signaling cascades. Acifran's chemical structure—(R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (C₁₂H₁₀O₄; MW 218.21)—is essential for this activity (APExBIO product page).

Evidence & Benchmarks

• Acifran binds selectively to both HCAR2 and HCAR3, with atomic-level structures resolved by cryo-EM (3.18 Å for HCAR3, 2.72 Å for HCAR2) (DOI:10.1371/journal.pbio.3003480).
• Key ligand–receptor interactions include π–π stacking with F107^3.32 (HCAR3) and size-selectivity due to pocket residue differences (V/L83^2.60, Y/N86^2.63, S/W91^2.48) (DOI:10.1371/journal.pbio.3003480).
• cAMP assays in HEK-293 cells confirm functional receptor activation by Acifran; responses are dose-dependent and reproducible under standard cell culture conditions (DOI:10.1371/journal.pbio.3003480).
• Acifran is supplied at ≥98% purity and shows stable performance when stored at -20°C, shipped on blue ice, and used promptly after solution preparation (APExBIO product page).
• Unlike some HCAR2 agonists, Acifran’s activation of HCAR3 avoids off-target side effects such as cutaneous flushing, facilitating focused lipid metabolism research (DOI:10.1371/journal.pbio.3003480).

Applications, Limits & Misconceptions

Acifran is employed in research focused on dissecting lipid signaling pathways and validating mechanisms underlying metabolic disorders. It is particularly useful for cell-based assays exploring receptor selectivity and downstream lipid regulation (n3-kethoxal.com). This article extends the discussion in entinostat.net by offering detailed structural and workflow integration guidance.

Common Pitfalls or Misconceptions

• Not for diagnostic or therapeutic use: Acifran is strictly for research; it is not approved for clinical or diagnostic applications (APExBIO).
• Limited solubility: Maximum solubility is <21.82 mg/ml in ethanol and DMSO; exceeding this leads to precipitation and assay variability.
• Stability constraints: Solutions should not be stored long-term; activity declines rapidly after preparation.
• Assay specificity: Non-selective use may confound results; controls for receptor expression are necessary (rilonaceptsource.com extends this discussion by highlighting optimal assay design).
• Species differences: Efficacy and selectivity are validated in human GPCRs; cross-species extrapolation is not guaranteed.

Workflow Integration & Parameters

Acifran integrates into GPCR and lipid metabolism research workflows as follows:

• Preparation: Dissolve immediately prior to use at concentrations up to 21.82 mg/ml in ethanol or DMSO; filter if necessary.
• Storage: Store powder at -20°C. Ship with blue ice. Avoid repeated freeze-thaw cycles (APExBIO).
• Assay design: Use in cAMP, cell viability, proliferation, and cytotoxicity assays with verified receptor expression. Reference n3-kethoxal.com, which this article updates with latest structural benchmarks.
• Controls: Include vehicle controls and known agonists for result validation.
• Documentation: Cite cryo-EM structural data (PDB: 9JKX, 9JKY) for atomic-level pathway mapping (Ye et al., 2025).

Conclusion & Outlook

Acifran, as supplied by APExBIO, is a structurally validated, high-purity HM74A/GPR109A and GPR109B agonist suitable for precise lipid metabolism research. Its well-characterized mechanism, reproducible activity, and workflow compatibility position it as a reference standard for dissecting lipid signaling and advancing metabolic disorder studies. Future research may leverage Acifran’s selectivity to design next-generation GPCR-targeted agents, avoiding off-target effects and enabling translational breakthroughs. For detailed product information and ordering, refer to the Acifran B6848 kit.

For advanced insights into translational opportunities and mechanistic pathways, see incb018424.com, which this article clarifies with up-to-date structural and workflow data.